A Prospective Multicenter Observational Study of Bevacizumab for the Treatment of Metastatic Colorectal Cancer in Chinese Patients (obtain Study).
Fenghua Wang,Guanghai Dai,Yanhong Deng,Yong Tang,Wei Wang,Zuoxing Niu,Feng Bi,Liangjun Zhu,Zengqing Guo,Jin Yan,Bing Hu,Min Tao,Shujun Yang,Suzhan Zhang,Lu Wen,Ruihua Xu
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e15560
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e15560 Background: Bevacizumab (BV) was approved in China seven years ago. Safety data from multicenter observational study was limited. To understand practical use of BV and confirm the correlation of prognostic factors with outcomes in Chinese patients (Pts) with mCRC, we have studied safety and efficacy of BV combined with 5-FU based chemotherapy (CT) in Pts with mCRC. Various subgroup analysis were considered in this study. Methods: The current study is a multicenter, prospective observational study. Pts were treated with BV plus 5-FU based CT for mCRC. The primary objective was to investigate the safety profile of the treatment. In the subgroup analysis, age, KRAS mutational status, peritoneal metastasis, primary tumor resection, metastatic status and blood pressure increasing were analyzed. Results: From Sep 2013 to Nov 2016, 613 Pts were accrued from 25 Chinese cites (median age 55 years (46–64); ECOG PS 0-1: 95.3%). Total 151 (24.63%) Pts experienced grade ≥ 3 AEs. AEs related to BV were reported in 46.98% of Pts. AESIs in this study were hypertension (1.96%), proteinuria (0.49%), bleeding (0.98%), GI perforation (0.33%), venous TE (0.16%) and fistula/abscess (1.14%). The median OS of all mCRC Pts was 18 months (95% CI, 16.99–20.07), (1st line 18 months (95% CI, 17.08–21.82); 2nd line 17.45 months (95% CI, 14.72–20.07)). The median PFS were 10.05 months (95% CI, 9.2%–11.37%), (1st line 11.04 months (95% CI, 9.66–13.34); 2nd line 8.74 months (95% CI, 7.49–10.58)). In the multivariate analysis of 1st line Pts and 2nd line Pts, peritoneal metastasis and blood pressure increasing were associated with OS, respectively. Age, KRAS mutation status, primary tumor location, primary tumor resection and metastatic status were not associated with OS in this population. Conclusions: The safety profile, such as BV-related AEs in this study seemed comparable with those reported from other pivotal studies or Chinese registration studies (ARTIST and REACT). BV combined with standard CT is effective. However, OS in1st line Pts was shorter than those studies. We will discuss this in future presentation and manuscript. Clinical trial information: NCT01912443.